PURPOSE: Delayed treatment after ischemia is often unsatisfactory. We hypothesized that injection of bone marrow stem cell (BMSC) conditioned medium after ischemia could rescue ischemic retina, and in this study we characterized the functional and histological outcomes and mechanisms of this neuroprotection. METHODS: Retinal ischemia was produced in adult Wistar rats by increasing intraocular pressure for 55 minutes. Conditioned medium (CM) from rat BMSCs or unconditioned medium (uCM) was injected into the vitreous 24 hours after the end of ischemia. Recovery was assessed 7 days after ischemia using electroretinography, at which time we euthanized the animals and then prepared 4-μm-thick paraffin-embedded retinal sections. TUNEL and Western blot were used to identify apoptotic cells and apoptosis-related gene expression 24 hours after injections; that is, 48 hours after ischemia. Protein content in CM versus uCM was studied using tandem mass spectrometry, and bioinformatics methods were used to model protein interactions. RESULTS: Intravitreal injection of CM 24 hours after ischemia significantly improved retinal function and attenuated cell loss in the retinal ganglion cell layer. CM attenuated postischemic apoptosis and apoptosis-related gene expression. By spectral counting, 19 proteins that met stringent identification criteria were increased in the CM compared to uCM; the majority were extracellular matrix proteins that mapped into an interactional network together with other proteins involved in cell growth and adhesion. CONCLUSIONS: By restoring retinal function, attenuating apoptosis, and preventing retinal cell loss after ischemia, CM is a robust means of delayed postischemic intervention. We identified some potential candidate proteins for this effect. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Delayed treatment after ischemia is often unsatisfactory. We hypothesized that injection of bone marrow stem cell (BMSC) conditioned medium after ischemia could rescue ischemic retina, and in this study we characterized the functional and histological outcomes and mechanisms of this neuroprotection. METHODS:Retinal ischemia was produced in adult Wistar rats by increasing intraocular pressure for 55 minutes. Conditioned medium (CM) from rat BMSCs or unconditioned medium (uCM) was injected into the vitreous 24 hours after the end of ischemia. Recovery was assessed 7 days after ischemia using electroretinography, at which time we euthanized the animals and then prepared 4-μm-thick paraffin-embedded retinal sections. TUNEL and Western blot were used to identify apoptotic cells and apoptosis-related gene expression 24 hours after injections; that is, 48 hours after ischemia. Protein content in CM versus uCM was studied using tandem mass spectrometry, and bioinformatics methods were used to model protein interactions. RESULTS: Intravitreal injection of CM 24 hours after ischemia significantly improved retinal function and attenuated cell loss in the retinal ganglion cell layer. CM attenuated postischemic apoptosis and apoptosis-related gene expression. By spectral counting, 19 proteins that met stringent identification criteria were increased in the CM compared to uCM; the majority were extracellular matrix proteins that mapped into an interactional network together with other proteins involved in cell growth and adhesion. CONCLUSIONS: By restoring retinal function, attenuating apoptosis, and preventing retinal cell loss after ischemia, CM is a robust means of delayed postischemic intervention. We identified some potential candidate proteins for this effect. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Matthew M Harper; Sinisa D Grozdanic; Bas Blits; Markus H Kuehn; Daniel Zamzow; Janice E Buss; Randy H Kardon; Donald S Sakaguchi Journal: Invest Ophthalmol Vis Sci Date: 2011-06-23 Impact factor: 4.799
Authors: John C Dreixler; Ajay Sampat; Afzhal R Shaikh; Michael Alexander; Marcus M Marcet; Steven Roth Journal: J Mol Neurosci Date: 2011-05-15 Impact factor: 3.444
Authors: Boyeon Lee; Douglas Clarke; Abraham Al Ahmad; Michael Kahle; Christi Parham; Lisa Auckland; Courtney Shaw; Mehmet Fidanboylu; Anthony Wayne Orr; Omolara Ogunshola; Andrzej Fertala; Sarah A Thomas; Gregory J Bix Journal: J Clin Invest Date: 2011-07-11 Impact factor: 14.808
Authors: John C Dreixler; Jacqueline N Poston; Afzhal R Shaikh; Michael Alexander; Kelsey Y Tupper; Marcus M Marcet; Myriam Bernaudin; Steven Roth Journal: Exp Eye Res Date: 2011-04-09 Impact factor: 3.467
Authors: Ilene K Sugino; Vamsi K Gullapalli; Qian Sun; Jianqiu Wang; Celia F Nunes; Noounanong Cheewatrakoolpong; Adam C Johnson; Benjamin C Degner; Jianyuan Hua; Tong Liu; Wei Chen; Hong Li; Marco A Zarbin Journal: Invest Ophthalmol Vis Sci Date: 2011-03-10 Impact factor: 4.799
Authors: Lars J Jensen; Michael Kuhn; Manuel Stark; Samuel Chaffron; Chris Creevey; Jean Muller; Tobias Doerks; Philippe Julien; Alexander Roth; Milan Simonovic; Peer Bork; Christian von Mering Journal: Nucleic Acids Res Date: 2008-10-21 Impact factor: 16.971
Authors: Elad Moisseiev; Johnathon D Anderson; Sharon Oltjen; Mayank Goswami; Robert J Zawadzki; Jan A Nolta; Susanna S Park Journal: Curr Eye Res Date: 2017-06-21 Impact factor: 2.424
Authors: Susanna S Park; Elad Moisseiev; Gerhard Bauer; Johnathon D Anderson; Maria B Grant; Azhar Zam; Robert J Zawadzki; John S Werner; Jan A Nolta Journal: Prog Retin Eye Res Date: 2016-10-23 Impact factor: 21.198